Skip to main content
Figure 2 | Journal of Immune Based Therapies and Vaccines

Figure 2

From: Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Figure 2

The percentage of sputum smear-negative patients in placebo and V5 arms administered in combination with TB drugs for one month. The upper paired bar shows conversion rate in placebo recipients (0%) in comparison to V5 recipients (78.3%) in a total number of enrolled patients (N = 34). Lower paired bars show conversion rates among first-diagnosed TB (1stDx); relapsed TB (RTB); and multidrug-resistant TB (MDR) respectively.

Back to article page
\